SpringerLink
Log in

RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Mitelman F, Johansson B, Mertens F Mitelman database of chromosome aberrations in cancer 2013. http://cgap.nci.nih.gov/Chromosomes/Mitelman.

  2. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.

    Article  CAS  Google Scholar 

  3. Warrell RP, Frankel SR, Miller WH, Scheinberg DA, Itri LM, Hittelman WN et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385–1393.

    Article  Google Scholar 

  4. Pui C-H, Relling MV, Downing JR . Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535–1548.

    Article  CAS  Google Scholar 

  5. Mrózek K, Heerema NA, Bloomfield CD . Cytogenetics in acute leukemia. Blood Rev 2004; 18: 115–136.

    Article  Google Scholar 

  6. Chase A, Ernst T, Fiebig A, Collins A, Grand F, Erben P et al. TFG, a target of chromosome translocations in lymphoma and soft tissue tumors, fuses to GPR128 in healthy individuals. Haematologica 2010; 95: 20–26.

    Article  CAS  Google Scholar 

  7. Iyer MK, Chinnaiyan AM, Maher CA . ChimeraScan: a tool for identifying chimeric transcription in sequencing data. Bioinformatics 2011; 27: 2903–2904.

    Article  CAS  Google Scholar 

  8. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013; 368: 2059–2074.

    Article  Google Scholar 

  9. Toffalini F, Demoulin J-B . New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. Blood 2010; 116: 2429–2437.

    Article  CAS  Google Scholar 

  10. Mossadegh-Keller N, Sarrazin S, Kandalla PK, Espinosa L, Stanley ER, Nutt SL et al. M-CSF instructs myeloid lineage fate in single haematopoietic stem cells. Nature 2013; 497: 239–243.

    Article  CAS  Google Scholar 

  11. Ridge SA, Worwood M, Oscier D, Jacobs A, Padua RA . FMS mutations in myelodysplastic, leukemic, and normal subjects. Proc Natl Acad Sci USA 1990; 87: 1377–1380.

    Article  CAS  Google Scholar 

  12. Gu T, Mercher T, Tyner JW, Goss VL, Walters DK, Cornejo MG et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 2007; 110: 323–333.

    Article  CAS  Google Scholar 

  13. Chase A, Schultheis B, Kreil S, Baxter J, Hidalgo-Curtis C, Jones A et al. Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1. Leukemia 2008; 23: 358–364.

    Article  Google Scholar 

  14. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Nat Med 1996; 2: 561–566.

    Article  CAS  Google Scholar 

  15. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E et al. Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580. Proc Natl Acad Sci USA 2005; 102: 16078–16083.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the Swedish Cancer Society, the Swedish Children’s Cancer Foundation, the Inga-Britt and Arne Lundberg Foundation, the Gunnar Nilsson Cancer Foundation, the Medical Faculty of Lund University and the Swedish Research Council (personal project grant to TF, Hemato-Linné and BioCARE strategic research program grants).

Author information

Authors and Affiliations

  1. Department of Clinical Genetics, University and Regional Laboratories, Lund University, Lund, Sweden

    H Lilljebjörn, H Ågerstam, C Orsmark-Pietras, M Rissler, H Ehrencrona & T Fioretos

  2. Department of Hematology and Coagulation, Skåne University Hospital, Lund, Sweden

    L Nilsson & J Richter

  3. Department of Molecular Medicine and Gene Therapy, Lund University, Lund, Sweden

    J Richter

Authors
  1. H Lilljebjörn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Ågerstam
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C Orsmark-Pietras
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Rissler
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Ehrencrona
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Nilsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. T Fioretos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to H Lilljebjörn or T Fioretos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lilljebjörn, H., Ågerstam, H., Orsmark-Pietras, C. et al. RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib. Leukemia 28, 977–979 (2014). https://doi.org/10.1038/leu.2013.324

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.324

  • Springer Nature Limited

This article is cited by

Search

Navigation